Literature DB >> 15499042

Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction.

Keiichi Kawamura1, Kazunobu Ishikawa, Youichiro Wada, Satoshi Kimura, Hayato Matsumoto, Takahide Kohro, Hiroyuki Itabe, Tatsuhiko Kodama, Yukio Maruyama.   

Abstract

OBJECTIVE: Heme oxygenase-1 (HO-1), the rate-limiting enzyme of heme degradation, has recently been considered to have protective roles against various pathophysiological conditions. Since we demonstrated that HO-1 overexpression inhibits atherosclerotic formation in animal models, we examined the effect of HO modulation on proinflammatory cytokine production, endothelial NO synthase (eNOS) expression, and endothelium-dependent vascular relaxation responses. METHODS AND
RESULTS: After HO-1 induction by heme arginate (HA), vascular endothelial cell cultures were exposed to oxidized low-density lipoprotein (oxLDL) or tumor necrosis factor-alpha (TNF-alpha). HA pretreatment significantly attenuated the production of vascular cell adhesion molecule-1, monocyte chemotactic protein-1, and macrophage colony-stimulating factor, suggesting that HO-1 induction attenuates proinflammatory responses. In addition, HO-1 overexpression also alleviated endothelial dysfunction as judged by restoration of attenuated eNOS expression after exposure to oxLDL and TNF-alpha. Importantly, impaired endothelium-dependent vascular relaxation responses in thoracic aortic rings from high-fat-fed LDL receptor knockout mice were also improved. These effects were observed by treatment with bilirubin not by carbon monoxide.
CONCLUSIONS: These results suggest that the antiatherogenic properties of HO-1 may be mediated predominantly through the action of bilirubin by inhibition of vascular endothelial activation and dysfunction in response to proinflammatory stresses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15499042     DOI: 10.1161/01.ATV.0000148405.18071.6a

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  78 in total

1.  Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

Authors:  Cheryl McDonald; Jonathan Uy; Wenhua Hu; Victoria Wirtz; Salome Juethner; David Butcher; Donnie McGrath; Awny Farajallah; Graeme Moyle
Journal:  AIDS Patient Care STDS       Date:  2012-03-09       Impact factor: 5.078

2.  Relationship between total bilirubin and endothelial function, inflammation and oxidative stress in HIV-infected adults on stable antiretroviral therapy.

Authors:  Co Hileman; Ct Longenecker; Tl Carman; Gl Milne; D E Labbato; Nj Storer; Ca White; Ga McComsey
Journal:  HIV Med       Date:  2012-05-25       Impact factor: 3.180

3.  Hyperbilirubinemia and intermittent lower urinary tract dysfunction.

Authors:  Vesna Stojanović; Tamara Vukavić
Journal:  Indian J Pediatr       Date:  2011-01-04       Impact factor: 1.967

4.  In vitro analysis of the effect of hyperbilirubinemia on rabbit ureter and bladder.

Authors:  Nergis Murat; Belde Kasap; Salih Kavukcu; Alper Soylu; Mehmet Türkmen; Sedef Gidener
Journal:  Pediatr Nephrol       Date:  2005-12-29       Impact factor: 3.714

5.  Hyperbilirubinemia and intermittent lower urinary tract dysfunction: a story.

Authors:  Viroj Wiwanitkit
Journal:  Indian J Pediatr       Date:  2011-03-05       Impact factor: 1.967

Review 6.  Heme oxygenase in the regulation of vascular biology: from molecular mechanisms to therapeutic opportunities.

Authors:  Young-Myeong Kim; Hyun-Ock Pae; Jeong Euy Park; Yong Chul Lee; Je Moon Woo; Nam-Ho Kim; Yoon Kyung Choi; Bok-Soo Lee; So Ri Kim; Hun-Taeg Chung
Journal:  Antioxid Redox Signal       Date:  2010-10-26       Impact factor: 8.401

7.  Bilirubin prevents acute DSS-induced colitis by inhibiting leukocyte infiltration and suppressing upregulation of inducible nitric oxide synthase.

Authors:  Stephen D Zucker; Megan E Vogel; Tammy L Kindel; Darcey L H Smith; Gila Idelman; Uri Avissar; Ganesh Kakarlapudi; Michelle E Masnovi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-09-17       Impact factor: 4.052

8.  Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  K H Chan; R L O'Connell; D R Sullivan; L S Hoffmann; K Rajamani; M Whiting; M W Donoghoe; M Vanhala; A Hamer; B Yu; R Stocker; M K C Ng; A C Keech
Journal:  Diabetologia       Date:  2013-01-17       Impact factor: 10.122

9.  Shorter GT repeat polymorphism in the heme oxygenase-1 gene promoter has protective effect on ischemic stroke in dyslipidemia patients.

Authors:  Chyi-Huey Bai; Jiunn-Rong Chen; Hou-Chang Chiu; Chia-Chi Chou; Lee-Young Chau; Wen-Harn Pan
Journal:  J Biomed Sci       Date:  2010-02-23       Impact factor: 8.410

10.  Antihypertensive actions of moderate hyperbilirubinemia: role of superoxide inhibition.

Authors:  David E Stec; Megan V Storm; Brandon E Pruett; Monette U Gousset
Journal:  Am J Hypertens       Date:  2013-03-12       Impact factor: 2.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.